Pollock A A, Tee P E, Patel I H, Spicehandler J, Simberkoff M S, Rahal J J
Antimicrob Agents Chemother. 1982 Nov;22(5):816-23. doi: 10.1128/AAC.22.5.816.
The multiple-dose pharmacokinetics and tolerance of intravenous ceftriaxone were investigated in 44 adults with normal renal function. Doses of 0.5, 1.0, and 2.0 g every 12 h and 2 g every 24 h were administered intravenously at a constant rate over 30 min. Plasma and urine samples were collected after the first (day 1) and last (day 4) dose and assayed for ceftriaxone by high-pressure liquid chromatography. Considering all four doses, mean peak plasma concentrations ranged from 79 to 255 micrograms/ml on day 1 and from 101 to 280 micrograms/ml on day 4. Trough concentrations at 12 h on day 1 were 15 to 45 micrograms/ml and 20 to 59 micrograms/ml on day 4. After a dose regimen of 2 g every 24 h, trough levels were still in the clinically therapeutic range (13 to 15 microgram/ml). The mean beta-phase t1/2 was markedly long (6.3 to 6.9 h) and was independent of dose. The fraction of dose excreted unchanged in the urine (0.33 to 0.44) indicated a substantial nonrenal mechanism of elimination. The plasma clearance ranged between 1,002 and 1,449 ml/h, and renal clearance ranged from 353 to 529 ml/h. The apparent volume of distribution varied from 9.2 to 13.5 liters. The dose-related increases in calculated Vd and Clp could be attributed to concentration-dependent plasma protein binding because of a larger free fraction of drug at higher concentrations. The drug was well tolerated, and no significant clinical or laboratory abnormalities were noted.
在44名肾功能正常的成年人中研究了静脉注射头孢曲松的多剂量药代动力学和耐受性。每12小时分别静脉注射0.5克、1.0克和2.0克剂量,以及每24小时静脉注射2克剂量,均以恒定速率在30分钟内输注。在首次(第1天)和末次(第4天)给药后采集血浆和尿液样本,采用高压液相色谱法测定头孢曲松含量。综合考虑所有四种剂量,第1天的平均血浆峰浓度范围为79至255微克/毫升,第4天为101至280微克/毫升。第1天12小时的谷浓度为15至45微克/毫升,第4天为20至59微克/毫升。在每24小时2克的给药方案后,谷浓度仍处于临床治疗范围内(13至15微克/毫升)。平均β相半衰期明显较长(6.3至6.9小时),且与剂量无关。经尿液以原形排泄的剂量分数(0.33至0.44)表明存在大量非肾排泄机制。血浆清除率范围为1002至1449毫升/小时,肾清除率范围为353至529毫升/小时。表观分布容积为9.2至13.5升。计算得出的Vd和Clp与剂量相关的增加可能归因于浓度依赖性血浆蛋白结合,因为在较高浓度下药物的游离分数更大。该药物耐受性良好,未观察到明显的临床或实验室异常。